9T1X | pdb_00009t1x

Plasmodium falciparum Aminopeptidase P in complex with hydroxamic-peptide based inhibitor 6d


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.55 Å
  • R-Value Free: 
    0.247 (Depositor), 0.228 (DCC) 
  • R-Value Work: 
    0.221 (Depositor), 0.222 (DCC) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 9T1X

This is version 1.0 of the entry. See complete history

Literature

Hydroxamate-based inhibitors reveal structural determinants of selectivity for Plasmodium falciparum aminopeptidase P.

Mills, B.J.Gregory, K.S.Cozier, G.E.Taweechai, S.Loughlan, E.McConkey, G.A.Isaac, R.E.Foster, R.Acharya, K.R.

(2026) J Biol Chem 302: 111372-111372

  • DOI: https://doi.org/10.1016/j.jbc.2026.111372
  • Primary Citation Related Structures: 
    9T1X, 9T1Y

  • PubMed Abstract: 

    The malarial parasite, Plasmodium falciparum (Pf), utilizes aminopeptidases in the breakdown of hemoglobin-derived oligopeptides to release amino acids for protein synthesis during growth and asexual reproduction of erythrocytic stages of the parasite. However, a N-terminal peptide bond that involves proline is difficult to hydrolyze. Aminopeptidase P (APP) is capable of cleaving peptide bonds with proline in the second position. Inhibition of PfAPP is therefore an attractive strategy for developing therapeutics for the treatment of malaria by limiting the supply of amino acids at the erythrocytic stage. We employed the structure-activity relationship of an existing APP inhibitor, apstatin, to design a more potent PfAPP inhibitor by introducing a hydroxamic acid metal-binding group in place of the amino-alcohol of apstatin and an aromatic P4' moiety. A hydroxamic tetrapeptide with phenylalanine at P4' (6d) greatly increased the inhibitory potency (apstatin K i , 16 μM; 6d, K i 685 nM). Replacing the P3' proline of 6d with a 2-substituted piperidine (6e) further improved the potency (K i , 24 nM). Crystal structure analysis of PfAPP in complex with 6d and 6e showed binding at the active site with coordination of the hydroxamic acid metal binding group to the di-metal center, and several protein-inhibitor interactions involving domains II and III. A comparison of PfAPP-6e with human APP1 indicated that the P4' phenylalanine drives inhibitor potency and selectivity toward PfAPP, by forming an interaction with Tyr617 of the adjacent monomer within the dimer. The details presented here should be useful for the future design of potent and selective PfAPP inhibitors.


  • Organizational Affiliation
    • School of Chemistry, University of Leeds, Leeds, UK.

Macromolecule Content 

  • Total Structure Weight: 153.68 kDa 
  • Atom Count: 10,267 
  • Modeled Residue Count: 1,255 
  • Deposited Residue Count: 1,324 
  • Unique protein chains: 2

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Aminopeptidase PA [auth B],
B [auth A]
657Plasmodium falciparum 3D7Mutation(s): 0 
Gene Names: APPPF14_0517PF3D7_1454400
EC: 3.4.11.9
UniProt
Find proteins for A0A144A2H0 (Plasmodium falciparum (isolate 3D7))
Explore A0A144A2H0 
Go to UniProtKB:  A0A144A2H0
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupA0A144A2H0
Sequence Annotations
Expand
Reference Sequence
Find similar proteins by:  Sequence   |   3D Structure  
Entity ID: 2
MoleculeChains  Sequence LengthOrganismDetailsImage
hydroxamic-peptide based inhibitorC,
D [auth E]
5synthetic constructMutation(s): 0 
Sequence Annotations
Expand
Reference Sequence

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.55 Å
  • R-Value Free:  0.247 (Depositor), 0.228 (DCC) 
  • R-Value Work:  0.221 (Depositor), 0.222 (DCC) 
Space Group: C 1 2 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 144.932α = 90
b = 94.081β = 105.494
c = 102.285γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
DIALSdata reduction
Aimlessdata scaling
PHASERphasing

Structure Validation

View Full Validation Report



Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
Not funded--

Revision History  (Full details and data files)

  • Version 1.0: 2026-09-23
    Type: Initial release